Arbutus Biopharma Corp. (ABUS)
4.07
-0.04
(-0.97%)
USD |
NASDAQ |
Nov 19, 16:00
4.085
+0.02
(+0.37%)
After-Hours: 20:00
Arbutus Biopharma Enterprise Value : 476.87M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 476.87M |
| November 18, 2026 | 484.84M |
| November 17, 2026 | 472.89M |
| November 16, 2026 | 470.89M |
| November 13, 2026 | 480.86M |
| November 12, 2026 | 468.90M |
| November 11, 2026 | 439.01M |
| November 10, 2026 | 427.05M |
| November 09, 2026 | 407.13M |
| November 06, 2026 | 394.17M |
| November 05, 2026 | 397.16M |
| November 04, 2026 | 474.88M |
| November 03, 2026 | 439.01M |
| November 02, 2026 | 462.92M |
| October 30, 2026 | 504.77M |
| October 29, 2026 | 518.72M |
| October 28, 2026 | 526.69M |
| October 27, 2026 | 520.71M |
| October 26, 2026 | 502.78M |
| October 23, 2026 | 502.78M |
| October 22, 2026 | 504.77M |
| October 21, 2026 | 498.79M |
| October 20, 2026 | 528.68M |
| October 19, 2026 | 508.76M |
| October 16, 2026 | 506.76M |
| Date | Value |
|---|---|
| October 15, 2026 | 520.71M |
| October 14, 2026 | 500.78M |
| October 13, 2026 | 484.84M |
| October 12, 2026 | 492.81M |
| October 09, 2026 | 506.76M |
| October 08, 2026 | 498.79M |
| October 07, 2026 | 520.71M |
| October 06, 2026 | 558.58M |
| October 05, 2026 | 596.44M |
| October 02, 2026 | 552.60M |
| October 01, 2026 | 574.52M |
| September 30, 2026 | 618.36M |
| September 29, 2026 | 837.90M |
| September 28, 2026 | 871.50M |
| September 25, 2026 | 869.53M |
| September 24, 2026 | 875.45M |
| September 23, 2026 | 869.53M |
| September 22, 2026 | 901.15M |
| September 21, 2026 | 899.17M |
| September 18, 2026 | 901.15M |
| September 17, 2026 | 913.00M |
| September 16, 2026 | 909.05M |
| September 15, 2026 | 911.03M |
| September 14, 2026 | 924.86M |
| September 11, 2026 | 922.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gossamer Bio, Inc. | 58.35M |
| ACADIA Pharmaceuticals, Inc. | 2.135B |
| Alnylam Pharmaceuticals, Inc. | 19.20B |
| Anika Therapeutics, Inc. | 159.06M |
| Savara, Inc. | 971.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 59.12M |
| Revenue (Quarterly) | 0.299M |
| Total Expenses (Quarterly) | -58.82M |
| EPS Diluted (Quarterly) | 0.2961 |
| Gross Profit Margin (Quarterly) | 96.66% |
| Earnings Yield | 27.52% |
| Operating Earnings Yield | 18.21% |
| Normalized Earnings Yield | 27.36 |